FrancophonIA/ELRC3.0 huggingface dataset:
English: Unopened vial of powder
Estonian: Pulbri avamata viaal 30 kuud
English: Phlebitis, Flushing, Pallor
Estonian: Sage flebiit, nahapunetus, kahvatus
English: Dizziness, vertigo, fatigue and blurred vision have shown as very common or common undesirable effects of mifamurtide treatment.
Estonian: Mifamurtiidiga ravi väga sagedased või sagedased kõrvaltoimed on pearinglus, vertiigo, väsimus ja nägemise hägustumine.
English: It is unknown whether mifamurtide is excreted in human milk.
Estonian: Mifamurtiidi eritumine inimese rinnapiima ei ole teada.
English: It has also been studied as part of assisted reproductive techniques in 470 women.
Estonian: Seda on samuti uuritud tehisviljastamises 470 naisel.
English: The European Commission granted a marketing authorisation valid throughout the European Union for GONAL-f to Merck Serono Europe Ltd. on 20 October 1995.
Estonian: Euroopa Komisjon andis ravimi GONAL-f müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Merck Serono Europe Ltd. 20. oktoobril 1995.
English: After the first injection, the patient or their partner may give the injections themselves, if they are well motivated, have been trained and have access to expert advice.
Estonian: Pärast esimest süsti võivad patsient või tema partner ravimit ise süstida, kui nad seda soovivad ja on saanud vastava väljaõppe ning kui neil on võimalik asjatundjalt nõu küsida.
English: Because these conditions are rare, GONAL-f was not compared with any other treatments in these studies, and the low number of patients in the studies was considered to be acceptable.
Estonian: Et neid haigusi esineb harva, ei võrreldud ravimit GONAL-f nendes uuringutes ühegi muu ravimiga ning uuringutes osalenud patsientide väikest arvu peeti piisavaks.
English: This is called ‘ovarian hyperstimulation syndrome'.
Estonian: Seda nimetatakse munasarja hüperstimulatsiooni sündroomiks.
English: In some women, the ovaries can over-respond to stimulation.
Estonian: Vahel võivad munasarjad stimulatsioonile üle reageerida.
English: GONAL-f follitropin alfa
Estonian: GONAL-f alfafollitropiin
English: The most common side effects with GONAL-f (seen in more than 1 patient in 10) are reactions at the injection site (pain, redness, bruising, swelling or irritation).
Estonian: Ravimi GONAL-f kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on süstekoha reaktsioon (valu, punetus, verevalum, turse ja ärritus).
English: In men, the studies looked at the number of men who started to produce sperm within the first 18 months of treatment.
Estonian: Meestel oli efektiivsuse põhinäitaja nende meeste arv, kellel hakkas tekkima sperma esimese 18 ravikuu jooksul.
English: • adult men who have hypogonadotrophic hypogonadism (a rare hormone deficiency disease).
Estonian: • täiskasvanud mehed, kellel on hüpogonadotroopne hüpogonadism (hormoonpuudulikkusest tingitud haruldane haigus).
English: The dose of GONAL-f and how often it is given depend on why it is being used and on the patient's response to treatment.
Estonian: Ravimi GONAL-f annus ja manustamissagedus sõltuvad sellest, milleks ravimit kasutatakse ja patsiendi ravivastusest.
English: The CHMP decided that GONAL-f's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et ravimi GONAL-f kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: It must not be used when it would not be possible for the patient to have an effective response, such as in patients whose ovaries or testicles do not work or in women who should not get pregnant for medical reasons.
Estonian: Seda ei tohi kasutada ka juhul, kui ravivastuse tekkimine patsiendil on võimatu, näiteks patsiendid, kellel puudub munasarjade- või munandite talitlus või naised, kes ei tohi tervislikel põhjustel rasestuda.
English: For more information about treatment with GONAL-f, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate ravimiga GONAL-f toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: In women, ovarian cysts (sacs of fluid within the ovaries) and headache are also seen in more than 1 patient in 10.
Estonian: Naistel on munasarjatsüstid (vedelikukogumid munasarjas) ja peavalu esinenud enam kui 1 patsiendil 10st.
English: If the powder is being used, it should be mixed with the solvent provided just before use.
Estonian: Pulber tuleb segada lahustiga vahetult enne kasutamist.
English: GONAL-f was as effective as human FSH in women who did not produce eggs or respond to clomiphene citrate: 84% of the women receiving GONAL-f produced eggs, compared with 91% of those receiving human FSH.
Estonian: GONAL-f oli sama efektiivne kui inimese FSH naistel, kellel ei tekkinud munarakke ning kelle ravi klomifeentsitraadiga ei andnud tulemusi: 84% naistest, kes said ravimit GONAL-f, tekkisid munarakud, FSH-d saanud naisel oli sama näitaja 91%.
English: GONAL-f is used to treat the following groups:
Estonian: Ravimit GONAL-f kasutatakse järgmistel patsiendirühmadel:
English: GONAL-f should not be used in people who may be hypersensitive (allergic) to follitropin alfa, FSH, or any of the other ingredients.
Estonian: Ravimit GONAL-f ei tohi kasutada inimesed, kes võivad olla alfafollitropiini, FSH või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: Previously, the FSH used in medicines was extracted from urine.
Estonian: Varem eraldati ravimina kasutatav FSH uriinist.
English: GONAL-f is a medicine that contains the active substance follitropin alfa.
Estonian: GONAL-f on ravim, mis sisaldab toimeainena alfafollitropiini.
English: This document is a summary of the European public assessment report (EPAR) for GONAL-f.
Estonian: Käesolev dokument on ravimi GONAL-f Euroopa avaliku hindamisaruande kokkuvõte.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for GONAL-f.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: What is GONAL-f?
Estonian: Mis on GONAL-f?
English: GONAL-f, in combination with LH, has also been studied in 38 women with severe LH and FSH deficiency, and in combination with hCG in 19 men with hypogonadotrophic hypogonadism.
Estonian: Ravimi GONAL-f kasutamist koos luteiniseeriva hormooniga (LH) on samuti uuritud 38 naisel, kellel on LH ja FSH raske puudulikkus ning koos inimese kooriongonadotropiiniga (hCG) 19 mehel, kellel on hüpogonadotroopne hüpogonadism.
English: In the body, FSH controls reproductive function: in women, it stimulates the production of eggs; and in men, it stimulates the production of sperm in the testicles.
Estonian: Organismis reguleerib FSH reproduktiivfunktsiooni: naistel stimuleerib FSH munasarjades munarakkude eraldumist ja meestel munandites sperma teket.
English: Treatment with GONAL-f should be carried out by a doctor who has experience in the treatment of fertility problems.
Estonian: Ravi GONAL-f-iga peab teostama viljakusprobleemide ravi kogemusega arst.
English: • adult women (aged 18 years or over) who do not produce eggs and do not respond to treatment with clomiphene citrate (another medicine that stimulates the ovaries to produce eggs);
Estonian: • vähemalt 18-aastased täiskasvanud naised, kellel ei teki munarakke ja kelle ravi klomifeentsitraadiga (samuti ovulatsiooni stimuleeriv ravim) ei ole andnud tulemusi;
English: Why has GONAL-f been approved?
Estonian: Miks GONAL-f heaks kiideti?
English: It is available as a solution for injection in a prefilled pen and as a powder and solvent that are made up into a solution for injection.
Estonian: Seda turustatakse süstelahusena eeltäidetud pensüstlas ning pulbri ja lahustina, millest valmistatakse süstelahus.
English: In these studies, GONAL-f was compared with human FSH that had been extracted from urine.
Estonian: Neis uuringutes võrreldi ravimit GONAL-f inimese FSH-ga, mis oli eraldatud uriinist.
English: GONAL-f is given by injection under the skin once a day.
Estonian: Ravimit GONAL-f manustatakse nahaaluse süstina üks kord ööpäevas.
English: In the studies of women, the main measures of effectiveness were the number of eggs collected, the number of women who released eggs and the number of follicles produced in the ovaries (small sacs that hold the eggs).
Estonian: Naiste uuringus oli efektiivsuse põhinäitaja eraldunud munarakkude ja munasarjas tekkinud folliikulite arv, ning nende naiste arv, kellel tekkisid munarakud.
English: It must not be used in patients with tumours of the pituitary gland or hypothalamus, or cancer of the breast, womb or ovary.
Estonian: Ravimit ei tohi kasutada patsiendid, kellel on hüpotalamuse-, hüpofüüsi- (ajuripatsi-), munasarja-, emaka või rinnanäärmekasvaja.
English: In women, GONAL-f must not be used when there is enlargement of an ovary or a cyst that is caused by something other than polycystic ovarian disease, or when there is unexplained bleeding from the vagina.
Estonian: Naised ei tohi ravimit GONAL-f kasutada laienenud munasarjade või sellise tsüsti korral, mis ei ole tingitud munasarjade polütsüstilisest haigusest, ega tupeverejooksu korral.
English: The follitropin alfa in GONAL-f is produced by a method known as ‘recombinant DNA technology': it is made by a cell that has received a gene (DNA), which makes it able to produce human FSH.
Estonian: Ravimis GONAL-f sisalduvat alfafollitropiini valmistatakse rekombinant-DNA-tehnika abil, seda toodab rakk, millele on lisatud inimese FSH tootmist võimaldav geen (DNA).
English: GONAL-f has been studied in 222 women who do not produce eggs or respond to clomiphene citrate.
Estonian: Ravimit GONAL-f uuriti 222 naisel, kellel ei teki munarakke ning kelle ravi klomifeentsitraadiga ei ole andnud tulemusi.
English: • adult women with severe deficiency (very low levels) of luteinising hormone (LH) and follicle stimulating hormone (FSH).
Estonian: • täiskasvanud naised, kellel on luteiniseeriva hormooni (lutropiin, LH) ja folliikuleid stimuleeriva hormooni (FSH) raske puudulikkus.
English: • adult women who are undergoing assisted reproductive techniques (fertility treatment) such as in-vitro fertilisation.
Estonian: • viljatusravi saavad täiskasvanud naised (tehisviljastamine, näiteks katseklaasis viljastamine).
English: What is the risk associated with GONAL-f?
Estonian: Mis riskid ravimiga GONAL-f kaasnevad?
English: GONAL-f is given together with a medicine containing LH to stimulate the eggs to mature in the ovaries;
Estonian: Ravimit GONAL-f manustatakse koos luteiniseerivat hormooni sisaldava ravimiga, et stimuleerida munarakkude küpsemist munasarjades;
English: For the full list of all side effects reported with GONAL-f, see the package leaflet.
Estonian: Ravimi GONAL-f kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: GONAL-f was also as effective as human FSH at stimulating the ovaries during assisted reproductive techniques.
Estonian: GONAL-f oli samuti sama efektiivne kui inimese FSH munasarjade stimuleerimisel tehisviljastamisel.
English: Other information about GONAL-f:
Estonian: Muu teave ravimi GONAL-f kohta
English: The full EPAR for GONAL-f can be found here.
Estonian: Euroopa avaliku hindamisaruande täistekst ravimi GONAL-f kohta on siin.
English: GONAL-f is used together with human chorionic gonadotrophin (hCG) to stimulate sperm production.
Estonian: Ravimit GONAL-f kasutatakse sperma tekke stimuleerimiseks koos inimese kooriongonadotropiiniga (hCG).
English: GONAL-f is given to stimulate the ovaries to produce more than one egg at a time;
Estonian: Ravimit GONAL-f manustatakse munasarjade stimuleerimiseks, et neis tekiks korraga mitu munarakku;
English: GONAL-f was effective in triggering egg development in women with severe LH and FSH deficiency.
Estonian: See käivitas efektiivselt ka munaraku arengu raske LF ning FSH puudulikkusega naistel.
English: How does GONAL-f work?
Estonian: Kuidas GONAL-f toimib?
English: The active substance in GONAL-f, follitropin alfa, is a copy of the natural hormone FSH.
Estonian: Ravimi GONAL-f toimeaine alfafollitropiin on loodusliku folliikuleid stimuleeriva hormooni (FSH) tehisvariant.
English: In the study in men, GONAL-f, used in combination with hCG, was effective in stimulating sperm production, with 63% of the men starting to produce sperm.
Estonian: Meeste uuringus oli GONAL-f kasutatuna koos hCG-ga efektiivne sperma tekke stimuleerimisel.
English: How has GONAL-f been studied?
Estonian: Kuidas ravimit GONAL-f uuriti?
English: What benefit has GONAL-f shown during the studies?
Estonian: Milles seisneb uuringute põhjal ravimi GONAL-f kasulikkus?
English: How is GONAL-f used?
Estonian: Kuidas ravimit GONAL-f kasutatakse?
English: What is GONAL-f used for?
Estonian: Milleks ravimit GONAL-f kasutatakse?
English: This dose may need to be increased after one or two weeks.
Estonian: Nädala või paari pärast võib olla vaja seda annust suurendada.
English: Repaglinide Teva is taken before meals, normally up to 15 minutes before each main meal.
Estonian: Repaglinide Tevat võetakse enne sööki, tavaliselt kuni 15 minutit enne söögikorra algust.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Repaglinide Teva to Teva Pharma B.V. on 29 June 2009.
Estonian: Euroopa Komisjon andis Repaglinide Teva müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Teva Pharma BV 29. juunil 2009.
English: Repaglinide Teva repaglinide EPAR summary for the public
Estonian: Repaglinide Teva repagliniid Kokkuvõte üldsusele
English: It is available as round tablets (blue: 0.5 mg; yellow: 1 mg; peach: 2 mg).
Estonian: Ravimit turustatakse ümmarguste tablettidena (sinised 0,5 mg, kollased 1 mg, kahvatuoranžid 2 mg).
English: The Committee recommended that Repaglinide Teva be given marketing authorisation.
Estonian: Komitee soovitas anda Repaglinide Tevale müügiloa.
English: A doctor should regularly test the patient's blood glucose to find the lowest effective dose.
Estonian: Arst peab patsiendi vereglükoosi sisaldust pidevalt kontrollima, et leida vähim efektiivne annus.
English: Type 2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively.
Estonian: II tüüpi suhkurtõbi on haigus, mille korral kõhunäärmes ei teki vere glükoosisisalduse reguleerimiseks piisavalt insuliini või kui organism ei suuda insuliini tõhusalt kasutada.
English: If patients are transferred from another anti-diabetes medicine, the recommended starting dose is 1 mg.
Estonian: Kui patsienti raviti enne muu diabeediravimiga, mis vahetatakse välja Prandini vastu, on soovitatav algannus 1 mg.
English: This means that Repaglinide Teva is similar to a ‘reference medicine' already authorised in the European Union (EU) called NovoNorm.
Estonian: See tähendab, et Repaglinide Teva on sarnane võrdlusravimiga NovoNorm, millel juba on Euroopa Liidus müügiluba.
English: Because Repaglinide Teva is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine (this means that the two medicines produce the same levels of the active substance in the body).
Estonian: Et Repaglinide Teva on geneeriline ravim, piirdusid uuringud katsetega, milles näidati Repaglinide Teva bioekvivalentsust võrdlusravimiga (mõlemad ravimid tekitavad organismis sama toimeainesisalduse).
English: Repaglinide Teva is a medicine that contains the active substance repaglinide.
Estonian: Repaglinide Teva on ravim, mis sisaldab toimeainena repagliniidi.
English: Because Repaglinide Teva is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.
Estonian: Et Repaglinide Teva on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Repaglinide Teva has been shown to have comparable quality and to be bioequivalent to NovoNorm.
Estonian: Inimravimite komitee otsustas, et vastavalt Euroopa Liidu nõuetele on tõendatud Repaglinide Teva võrdväärne kvaliteet ja bioekvivalentsus ravimiga NovoNorm.
English: The full EPAR for Repaglinide Teva can be found here.
Estonian: Euroopa avaliku hindamisaruande täisteksti Repaglinide Teva kohta leiate siit.
English: Repaglinide Teva is a ‘generic medicine'.
Estonian: Repaglinide Teva on geneeriline ravim.
English: It is used together with diet and exercise to lower blood glucose (sugar) levels in patients whose hyperglycaemia (high blood glucose levels) cannot be controlled by diet, weight reduction and exercise.
Estonian: Repaglinide Tevat kasutatakse koos dieedi ja kehaliste harjutustega, et alandada vere glükoosisisaldust (nn veresuhkrut) patsientidel, kelle hüperglükeemiat (vere liigset glükoosisisaldust) ei ole võimalik ainuüksi dieedi, kaalu alandamise ja kehaliste harjutustega kontrolli all hoida.
English: What are the benefit and risk of Repaglinide Teva?
Estonian: Milles seisneb Repaglinide Teva kasulikkus ja mis riskid Repaglinide Tevaga kaasnevad?
English: Therefore, the CHMP's view was that, as for NovoNorm, the benefit outweighs the identified risk.
Estonian: Seetõttu arvas inimravimite komitee, et nagu ka NovoNormi korral, ületab Repaglinide Teva kasulikkus sellega kaasnevad riskid.
English: Other information about Repaglinide Teva:
Estonian: Muu teave Repaglinide Teva kohta
English: Why has Repaglinide Teva been approved?
Estonian: Miks Repaglinide Teva heaks kiideti?
English: What is Repaglinide Teva?
Estonian: Mis on Repaglinide Teva?
English: Repaglinide Teva helps the pancreas to produce more insulin at mealtimes and is used to control type 2 diabetes.
Estonian: Repaglinide Teva soodustab insuliini tekkimist kõhunäärmes söögi ajal ning seda kasutatakse II tüüpi suhkurtõve raviks.
English: Repaglinide Teva is used in patients who have type 2 diabetes (non-insulin-dependent diabetes).
Estonian: Repaglinide Tevat kasutatakse II tüüpi diabeediga (insuliinisõltumatu suhkurtõvega) patsientide raviks.
English: Repaglinide Teva can also be used for type 2 diabetes patients whose blood glucose levels are usually controlled well on diet, but are experiencing temporary loss of blood glucose control.
Estonian: Repaglinide Tevat saab kasutada ka nende II tüüpi suhkurtõvega patsientide ravimiseks, kellel saab dieediga glükoosi sisaldust veres tavaliselt reguleerida, kuid mis dieediga reguleerimisele ajuti siiski ei allu.
English: Repaglinide Teva may also be used with metformin (another anti-diabetes medicine) in type 2 diabetes patients whose blood glucose levels are not satisfactorily controlled on metformin alone.
Estonian: Repaglinide Tevat võib kasutada ka koos metformiiniga (samuti diabeediravim) II tüüpi suhkurtõvega patsientidel, kellel ravi ainult metformiiniga ei anna rahuldavaid tulemusi.
English: How has Repaglinide Teva been studied?
Estonian: Kuidas Repaglinide Tevat uuriti?
English: How is Repaglinide Teva used?
Estonian: Kuidas Repaglinide Tevat kasutatakse?
English: What is Repaglinide Teva used for?
Estonian: Milleks Repaglinide Tevat kasutatakse?
English: How does Repaglinide Teva work?
Estonian: Kuidas Repaglinide Teva toimib?
English: The full EPAR for Aerius can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Aeriuse kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Aerius on 15 January 2001.
Estonian: Euroopa Komisjon andis Aeriuse müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 15. jaanuaril
English: Other information about Aerius
Estonian: Muu teave Aeriuse kohta
English: This is a summary of the European public assessment report (EPAR) for Aerius.
Estonian: See on ravimi Aerius Euroopa avaliku hindamisaruande kokkuvõte.
English: Aerius has also been studied in 416 patients with urticaria.
Estonian: Aeriust uuriti ka 416 urtikaariaga (nõgestõvega) patsiendil.
English: Aerius has been studied in a total of eight studies involving about 4,800 adult and adolescent patients with allergic rhinitis (including four studies in seasonal allergic rhinitis, and two studies in patients who also had asthma).
Estonian: Aeriust uuriti kokku 8 uuringus, milles osales ligikaudu 4800 täiskasvanut ja noorukit, kellel oli allergiline riniit (sh 4 uuringus uuriti hooajalist allergilist riniiti ja 2 uuringus patsiente, kellel oli ka astma).
English: In all studies, the effectiveness of Aerius was compared with that of placebo (a dummy treatment).
Estonian: Kõigis uuringuis võrreldi Aeriuse efektiivsust platseebo (näiva ravimi) efektiivsusega.
English: For more information about treatment with Aerius, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Aeriusega toimuva ravi kohta lisateavet, lugege pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Aerius is a medicine containing the active substance desloratadine.
Estonian: Aerius on ravim, mis sisaldab toimeainena desloratadiini.
English: What is Aerius?
Estonian: Mis on Aerius?
English: The active substance in Aerius, desloratadine, is an antihistamine.
Estonian: Aeriuse toimeaine desloratadiin on antihistamiin.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Aerius.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Aerius must not be used in people who are hypersensitive (allergic) to desloratadine, loratadine or any of the other ingredients.
Estonian: Aeriust ei tohi kasutada patsiendid, kes on desloratadiini, loratadiini või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: For the full list of all side effects reported with Aerius, see the package leaflet.
Estonian: Aeriuse kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: What is the risk associated with Aerius?
Estonian: Mis riskid Aeriusega kaasnevad?
English: The CHMP decided that Aerius's benefits are greater than its risks for the relief of symptoms associated with allergic rhinitis or urticaria and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Aeriuse kasulikkus allergilise riniidi või urtikaaria sümptomite leevendamisel on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: The effectiveness of Aerius was measured by looking at the change in the symptoms (nasal discharge, itching, sneezing and congestion) before and after two or four weeks of treatment.
Estonian: Aeriuse efektiivsust hinnati sümptomite (ninaeritised, sügelus, aevastamine ja ninakinnisus) muutuste põhjal enne ja pärast kahe- või neljanädalast ravi.
English: Aerius is used to relieve the symptoms of allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) or urticaria (a skin condition caused by an allergy, with symptoms including itching and hives).
Estonian: Aeriust kasutatakse allergilise riniidi (allergiast, nt heinapalavikust või tolmulestaallergiast põhjustatud ninaõõnepõletik) või nõgestõve (allergiast põhjustatud nahaseisund, mille sümptomid on sügelus ja nahakublad) sümptomite leevendamiseks.